Thyroid nodule medical therapy: Difference between revisions
No edit summary |
|||
| Line 9: | Line 9: | ||
==Medical Therapy== | ==Medical Therapy== | ||
{{familytree/start}} | |||
{{familytree | | | | | | | | | A01 | | | | | |A01=Thyroid nodule}} | |||
{{familytree | | | | | | | | | |!| | | | | | | | }} | |||
{{familytree | | |,|-|-|-|-|-|-|^|-|-|-|-|-|-|.| }} | |||
{{familytree | | C01 | | | | | | | | | | | | C03 |C01= Malignant |C03= Benign}} | |||
{{familytree | | |!| | | | | | | | | | | | | |!| | |}} | |||
{{familytree | | C01 | | | | | | | | | | | | C02 | | | C01= Radioiodine therapy | C02 = Hyrperthyroidism evaluation}} | |||
{{familytree | | | | | | | | | | | | | | |,|-|^|-|.|}} | |||
{{familytree | | | | | | | | | | | | | | C02 | | C03 | C02= Hyperthyroidism | C03 = Euthyroid }} | |||
{{familytree | | | | | | | | | | | | | | |!| | | |!| | }} | |||
{{familytree | | | | | | | | | | | | | | C02 | | C03 | C02= Antithyroid drugs | C03 = No medical treatment required <br> Monitor nodule }} | |||
{{familytree/end}} | |||
The goals of initial therapy of differentiated thyroid cancer (DTC) include: | The goals of initial therapy of differentiated thyroid cancer (DTC) include: | ||
Revision as of 13:51, 31 August 2017
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
|
Thyroid nodule Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Thyroid nodule medical therapy On the Web |
|
American Roentgen Ray Society Images of Thyroid nodule medical therapy |
|
Risk calculators and risk factors for Thyroid nodule medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Medical Therapy
| Thyroid nodule | |||||||||||||||||||||||||||||||||||||||||
| Malignant | Benign | ||||||||||||||||||||||||||||||||||||||||
| Radioiodine therapy | Hyrperthyroidism evaluation | ||||||||||||||||||||||||||||||||||||||||
| Hyperthyroidism | Euthyroid | ||||||||||||||||||||||||||||||||||||||||
| Antithyroid drugs | No medical treatment required Monitor nodule | ||||||||||||||||||||||||||||||||||||||||
The goals of initial therapy of differentiated thyroid cancer (DTC) include:
- To remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes. Completeness of surgical resection is an important determinant of outcome, while residual metastatic lymph nodes represent the most common site of disease persistence=recurrence[1] [2][3]
- To minimize treatment-related morbidity. The extent of surgery and the experience of the surgeon both play important roles in determining the risk of surgical complications[4]
- To permit accurate staging of the disease. Because disease staging can assist with initial prognostication, disease management, and follow-up strategies, accurate postoperative staging is a crucial element in the management of patients with DTC [5][6]
- To facilitate postoperative treatment with radioactive iodine, where appropriate. For patients undergoing RAI remnant ablation, or RAI treatment of residual or metastatic disease, removal of all normal thyroid tissue is an important element of initial surgery . Near total or total thyroidectomy also may reduce the risk for recurrence within the contralateral lobe [7][8]
- To permit accurate long-term surveillance for disease recurrence. Both RAI whole-body scanning (WBS) and measurement of serum Tg are affected by residual normal thyroid tissue. Where these approaches are utilized for long-term monitoring, near-total or totalthyroidectomy is required[9]
- To minimize the risk of disease recurrence and metastatic spread. Adequate surgery is the most important treatment variable influencing prognosis, while radioactive iodine treatment, TSH suppression, and external beam irradiation each play adjunctive roles in at least some patients[10]
It is recommended to use thryoid hormone in iodine insufficient areas as a treatment for benign thyroid nodules. Thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake but in iodine sufficient areas, there are insufficient evidence of beneficial effect of thyroid hormone treatment for benign thyroid nodules In pregnant women with FNA that is suspicious for or diagnostic of PTC, consideration could be given to administration of LT4 therapy to keep the TSH in the range of 0.1–1 mU=L[11][12]
postoperative RAI remnant ablation
Ablation of the remaining lobe with radioactive iodine has been used as an alternative to completion thyroidectomy[13]
Recombinant human TSH–mediated therapy
Recombinant human TSH–mediated therapy may be indicated in selected patients with underlying comorbidities making iatrogenic hypothyroidism potentially risky, in patients with pituitary disease who are unable to raise their serum TSH, or in patients in whom a delay in therapy might be deleterious. Such patients should be given the same or higher activity that would have been given had they been prepared with hypothyroidism or a dosimetrically determined activity[14]
Metastases treatment:
Treatment of endocrine metastases should be based on:
- Size of metastatic lesions (macronodular typically detected by chest radiography; micronodular typically detected by CT; lesions beneath the resolution of CT)
- Avidity for RAI and, if applicable, response to prior RAI therapy
- Stability absence of metastatic lesions
| Metastases | Treatment | |
|---|---|---|
| pulmonary metastases | Micrometastases | RAI therapy, and repeated every 6–12 months as long as disease continues to concentrate RAI and respond clinically, because the highest rates of complete remission are reported in these subgroups |
| macronodular metastases | RAI and treatment should be repeated when objective benefit is demonstrated (decrease in the size of the lesions, decreasing Tg), but complete remission is not common and survival remains poor. The selection of RAI activity to administer can be made empirically (100–200 mCi) or estimated by lesional dosimetry or dosimetry to limit wholebody retention to 80 mCi at 48 hours and 200 cGy to the red bone marrow. | |
| brain metastases | Complete surgical resection of CNS metastases should be considered regardless of RAI avidity
CNS lesions that are not amenable to surgery should be considered for external beam irradiation. Whole brain and spine irradiation could be considered if multiple metastases are present. | |
| bone metastases | Complete surgical resection of isolated symptomatic metastases
RAI therapy of iodine-avid bone metastases | |
Pulmonary pneumonitis and fibrosis are rare complications of high-dose radioactive iodine treatment
References
- ↑ Wang TS, Dubner S, Sznyter LA, Heller KS (2004). "Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes". Arch. Otolaryngol. Head Neck Surg. 130 (1): 110–3. doi:10.1001/archotol.130.1.110. PMID 14732779.
- ↑ Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993). "Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989". Surgery. 114 (6): 1050–7, discussion 1057–8. PMID 8256208.
- ↑ Ito Y, Miyauchi A (2010). "Thyroidectomy and lymph node dissection in papillary thyroid carcinoma". J Thyroid Res. 2011: 634170. doi:10.4061/2011/634170. PMC 2989453. PMID 21113383.
- ↑ Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R (1998). "The importance of surgeon experience for clinical and economic outcomes from thyroidectomy". Ann. Surg. 228 (3): 320–30. PMC 1191485. PMID 9742915.
- ↑ Carhill AA, Litofsky DR, Ross DS, Jonklaas J, Cooper DS, Brierley JD, Ladenson PW, Ain KB, Fein HG, Haugen BR, Magner J, Skarulis MC, Steward DL, Xing M, Maxon HR, Sherman SI (2015). "Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012". J. Clin. Endocrinol. Metab. 100 (9): 3270–9. doi:10.1210/JC.2015-1346. PMC 5393522. PMID 26171797.
- ↑ Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR (2002). "Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients". World J Surg. 26 (8): 879–85. doi:10.1007/s00268-002-6612-1. PMID 12016468.
- ↑ Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY (1998). "Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation". Am. J. Clin. Oncol. 21 (1): 77–81. PMID 9499265.
- ↑ Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB (2001). "Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis". Surgery. 130 (6): 921–30. doi:10.1067/msy.2001.118370. PMID 11742318.
- ↑ Mazzaferri EL (1999). "An overview of the management of papillary and follicular thyroid carcinoma". Thyroid. 9 (5): 421–7. doi:10.1089/thy.1999.9.421. PMID 10365671.
- ↑ Kim TH, Yang DS, Jung KY, Kim CY, Choi MS (2003). "Value of external irradiation for locally advanced papillary thyroid cancer". Int. J. Radiat. Oncol. Biol. Phys. 55 (4): 1006–12. PMID 12605980.
- ↑ Kuy S, Roman SA, Desai R, Sosa JA (2009). "Outcomes following thyroid and parathyroid surgery in pregnant women". Arch Surg. 144 (5): 399–406, discussion 406. doi:10.1001/archsurg.2009.48. PMID 19451480.
- ↑ Rosen IB, Korman M, Walfish PG (1997). "Thyroid nodular disease in pregnancy: current diagnosis and management". Clin Obstet Gynecol. 40 (1): 81–9. PMID 9103951.
- ↑ Randolph GW, Daniels GH (2002). "Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid". Thyroid. 12 (11): 989–96. doi:10.1089/105072502320908321. PMID 12490076.
- ↑ Braga M, Ringel MD, Cooper DS (2001). "Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration". J. Clin. Endocrinol. Metab. 86 (11): 5148–51. doi:10.1210/jcem.86.11.8055. PMID 11701668.